Q8N6T7 (SIR6_HUMAN) Homo sapiens (Human)
NAD-dependent protein deacylase sirtuin-6 UniProtKBInterProSTRINGInteractive Modelling
355 aa; Sequence (Fasta) ; (Isoform 2)
It is possible new templates exist for this target since these models were created.
Available Structures
43 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Human SIRT6 in complex with allosteric activator MDL-801 |
Heteromer P68431; | 100 | 1×AR6; 1×8L9; 1×ZN; 5×GOL; 7×SO4; 1×PEG; 1×HDR; | |||
| The novel de-long chain fatty acid function of human sirt6 |
Heteromer P68431; | 99.66 | 1×ZN; 1×APR; 2×GOL; | |||
| SIRT6 bound to an H3K9Ac nucleosome |
Heteromer P02281; P06897; P62799; P84233; | 100 | 1×ZSL; 1×ZN; | |||
| Structure of nucleosome-bound Sirtuin 6 deacetylase |
Heteromer P04908; P06899; P62799; P84233; | 99.63 | ||||
| Nucleosome Bound human SIRT6 (Composite) |
Heteromer P02281; P06897; P62799; P84233; | 100.0 | 1×ZN; | |||
| Human Sirt6 in complex with ADP-ribose and the inhibitor 2-Pr | homo-6-mer | 100.0 | 6×AR6; 6×ZN; 3×A1IIZ; 21×SO4; | |||
| Human SIRT6 in complex with inhibitor 7702 | homo-6-mer | 100.0 | 9×PG4; 6×O5L; 6×AR6; 6×ZN; 15×SO4; | |||
| Improved complex structure of human Sirtuin 6 with its inhibitor cis-resveratrol | homo-2-mer | 100.0 | 2×AR6; 2×ZN; 2×STL; 1×PG4; 2×EDO; 9×SO4; 6×CL; 1×PEG; 1×PGE; | |||
| Human Sirt6 in complex with the inhibitor S6020 and ADP-ribose | homo-2-mer | 100.0 | 2×AR6; 2×ZN; 1×EDO; 2×PEG; 8×SO4; 2×V7R; 2×CL; | |||
| Human Sirt6 in complex with ADP-ribose and the inhibitor catechin gallate | homo-2-mer | 100.0 | 2×AR6; 2×ZN; 1×EDO; 7×SO4; 2×XEG; | |||
| Human Sirt6 13-308 in complex with ADP-ribose and the activator fluvastatin | homo-2-mer | 100.0 | 2×AR6; 2×ZN; 2×GOL; 9×SO4; 1×115; | |||
| Human SIRT6 in complex with allosteric activator MDL-801 (3.2A) | monomer | 100 | 1×AR6; 1×ZN; 1×8L9; 4×GOL; 2×SO4; 1×PEG; 1×G4X; | |||
| Human Sirt6 3-318 in complex with ADP-ribose | monomer | 100.0 | 1×AR6; 1×ZN; 1×NCA; 2×GOL; 2×SO4; | |||
| Crystal structure of human SIRT6 | monomer | 100 | 1×AR6; 1×ZN; 8×SO4; 8×EDO; 1×G4U; 1×PEG; | |||
| Sirt6 apo structure | monomer | 100 | 1×AR6; 1×ZN; 2×TBU; 1×GOL; | |||
| Human Sirt6 in complex with ADP-ribose and fragment 4-hydroxybenzamide | monomer | 100.0 | 1×AR6; 1×ZN; 2×PEG; 1×P6G; 4×SO4; 1×HBD; 2×CL; | |||
| Human Sirt6 in complex with ADP-ribose and fragment 1-methyl-L-histidine | monomer | 100.0 | 1×AR6; 1×ZN; 1×HIC; 1×PEG; 3×SO4; | |||
| Human Sirt6 in complex with ADP-ribose and fragment cis-resveratrol | monomer | 100.0 | 1×AR6; 1×ZN; 1×STL; 1×PEG; 6×SO4; 1×PGE; 4×CL; | |||
| Human Sirt6 in complex with ADP-ribose and fragment 6-O-methylguanine | monomer | 100.0 | 1×AR6; 1×ZN; 1×6GO; 1×EDO; 1×PG4; 1×PEG; 6×SO4; 2×CL; | |||
| Human Sirt6 in complex with the inhibitor S6023 and ADP-ribose | monomer | 100.0 | 1×AR6; 1×ZN; 1×QTI; 4×SO4; 3×CL; | |||
| Human Sirt6 in complex with ADP-ribose and fragment 4-amino-6-chlorobenzene-1,3-disulfonamide | monomer | 100.0 | 1×AR6; 1×ZN; 1×PG4; 1×EDO; 1×PEG; 7×SO4; 1×I7B; 1×CL; | |||
| Human Sirt6 in complex with ADP-ribose and fragment nicotinamide | monomer | 100.0 | 1×AR6; 1×ZN; 1×NCA; 1×EDO; 1×PEG; 3×SO4; | |||
| Human Sirt6 in complex with ADP-ribose and fragment 3-(acetylamino)thiophene-2-carboxylic acid | monomer | 100.0 | 1×AR6; 1×ZN; 2×PEG; 3×SO4; 1×GV9; 2×CL; | |||
| Human Sirt6 in complex with ADP-ribose and the activator quercetin | monomer | 100.0 | 1×AR6; 1×ZN; 5×SO4; 1×QUE; 2×EDO; 1×PG4; | |||
| Human Sirt6 in complex with activator UBCS039 | monomer | 100.0 | 1×AR6; 1×ZN; 4×SO4; 2×EDO; 1×PGE; 1×7M2; | |||
| Human Sirt6 in complex with ADP-ribose and the activator isoquercetin | monomer | 100.0 | 1×AR6; 1×ZN; 5×SO4; 1×HW2; 4×EDO; | |||
| Human Sirt6 in complex with ADP-ribose and fragment Isatin | monomer | 100.0 | 1×AR6; 1×ZN; 1×EDO; 1×PG4; 4×SO4; 1×ISN; 1×CL; | |||
| Human Sirt6 13-308 in complex with ADP-ribose and the activator MDL-801 | monomer | 100.0 | 1×AR6; 1×ZN; 1×8L9; 5×SO4; | |||
| Human Sirt6 in complex with ADP-ribose and fragment 3-aminobenzamide | monomer | 100.0 | 1×AR6; 1×ZN; 2×PEG; 4×SO4; 1×3AB; 1×CL; | |||
| Human Sirt6 in complex with activator UBCS58 | monomer | 100.0 | 1×AR6; 1×ZN; 5×SO4; 2×EDO; 1×PG4; 1×7M5; | |||
| Human Sirt6 in complex with ADP-ribose and fragment sulfamethoxazole | monomer | 100.0 | 1×AR6; 1×ZN; 1×08D; 1×PEG; 3×EDO; 4×SO4; | |||
| Human Sirt6 in complex with the inhibitor S6039 and ADP-ribose | monomer | 100.0 | 1×AR6; 1×ZN; 1×QY3; 1×PEG; 4×SO4; 2×CL; | |||
| Human Sirt6 in complex with activator UBCS38 | monomer | 100.0 | 1×AR6; 1×ZN; 5×SO4; 1×EDO; 1×7N2; | |||
| Human Sirt6 in complex with small molecule UBCS40 | monomer | 100.0 | 1×AR6; 1×ZN; 3×SO4; 1×7M9; | |||
| Human Sirt6 in complex with ADP-ribose and fragment pyroglutamic acid | monomer | 100.0 | 1×AR6; 1×ZN; 1×PCA; 1×EDO; 1×PGE; 4×SO4; | |||
| Human Sirt6 13-308 in complex with ADP-ribose | monomer | 100.0 | 1×AR6; 1×ZN; 1×PGE; 5×SO4; | |||
| Human Sirt6 in complex with ADP-ribose and fragment 4-nitrocatechol | monomer | 100.0 | 1×AR6; 1×ZN; 1×4NC; 2×EDO; 2×SO4; | |||
| Human Sirt6 in complex with ADP-ribose and the inhibitor trichostatin A | monomer | 100.0 | 1×AR6; 1×ZN; 1×PG4; 1×EDO; 4×SO4; 1×TSN; | |||
| Human SIRT6 crystal structure in complex with ADP ribose | monomer | 99.65 | 2×UNX; 1×ZN; 1×AR6; 5×SO4; | |||
| Human Sirt6 3-318 in complex with ADP-ribose and the activator MDL-801 | monomer | 100.0 | 1×AR6; 1×ZN; 1×GOL; 1×8L9; 1×SO4; | |||
| Human Sirt6 in complex with ADP-ribose and the activator cyanidin | monomer | 100.0 | 1×AR6; 1×ZN; 3×EDO; 4×SO4; 1×HWB; | |||
| Human SIRT6 crystal structure in complex with 2'-N-Acetyl ADP ribose | monomer | 99.64 | 1×A2N; 1×ZN; 1×SO4; 3×UNX; | |||
| Crystal Structure of Human SIRT6 | monomer | 100.0 | 1×ZN; 1×APR; 4×SO4; 3×UNX; | |||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7cl1.1.A | monomer | 0.89 | 1×THR; 1×AR6; 1×ZN; 1×8L9; | 100.00 | ||
2 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 7cl1.1.A | monomer | 0.85 | 1×AR6; 1×8L9; | 97.87 | ||
| Isoform 2 | 6qcn.1.A | monomer | 0.50 | 37.25 | |||